Howard, following is an excerpt from your article - " I asked Jeremy Grummet, MD, Deputy Director of Urology at Alfred Health in Melbourne and an international leader in trying to stop transperineal biopsies and its risk of sepsis, ...." I believe you meant to state that Dr Grummet is trying to stop TRANSRECTAL (TR) biopsies. You provide a great service to prostate patients, and are also a leader in support of Transperineal Biopsies. I did not want the typo in your article to cause any confusion to casual readers of The Active Surveillor. Thank you.
Time to amp up the genetic tests, the 'liquid biopsy'. LynxDX is showing promise. I was surprised that LynxDX doesn't require a 'vigorous DRE' like SelectDX. In fact, you can produce the sample (urine) at home and send it in.
Again - there's zero irrefutable and reproducible data that supports the claim that the testing for and treatment of localized prostate cancers saves significant numbers of lives.
Howard, following is an excerpt from your article - " I asked Jeremy Grummet, MD, Deputy Director of Urology at Alfred Health in Melbourne and an international leader in trying to stop transperineal biopsies and its risk of sepsis, ...." I believe you meant to state that Dr Grummet is trying to stop TRANSRECTAL (TR) biopsies. You provide a great service to prostate patients, and are also a leader in support of Transperineal Biopsies. I did not want the typo in your article to cause any confusion to casual readers of The Active Surveillor. Thank you.
Thanks, William.
Someone else caught it.
I corrected it earlier and let Dr. Grummet know.
Thanks.
Howard
Time to amp up the genetic tests, the 'liquid biopsy'. LynxDX is showing promise. I was surprised that LynxDX doesn't require a 'vigorous DRE' like SelectDX. In fact, you can produce the sample (urine) at home and send it in.
Again - there's zero irrefutable and reproducible data that supports the claim that the testing for and treatment of localized prostate cancers saves significant numbers of lives.